Effect of Cyclophosphoramide, 6-Mercaptopurine, Actinomycin D and Vincaleukoblastine on the Acquisition of Delayed Hypersensitivity (DNCB Contact Dermatitis) in the Guinea-Pig11From the Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia 4, Pennsylvania.This study was supported in part by U.S.P.H.S. Training Grant 2 G-62.This investigation was carried out during the tenure of a postdoctoral fellowship, held by Dr. Maibach, from the Division of General Medical Sciences, United States Public Health Service.Cyclophosphoramide (Cytoxan®) was supplied by Paul A. Walter, M.D., Mead Johnson Laboratories, Evansville 21, Indiana; 6-mercaptopurine by Donald S. Searle, M.D., Burroughs Wellcome & Co., Tuckahoe, N.Y.; vincaleukoblastine by J. A. Armstrong, M.D., Eli Lilly and Co., Indianapolis 6, Indiana; and Actinomycin D by Elmer Alpert, M.D., Merck Sharp and Dohme, West Point, Pa.Presented at the Twenty-second Annual Meeting of The Society for Investigative Dermatology, Inc., New York, N.Y., June 28, 1961.  by Maguire, Henry C. & Maibach, Howard I.
EFFECT OF CYCLOPHOSPHORAMIDE, 6-MERCAPTOPURINE, ACTINOMYCIN
D AND VINCALEUKOBLASTINE ON THE ACQUISITION OF
DELAYED HYPERSENSITIVITY (DNCB CONTACT
DERMATITIS) IN THE GUINEAPIG*
HENRY C. MAGUIRE, JR., M.D. AND HOWARD I. MAIBACH, M.D.
Immediate type allergy deals with antibodies
that are relatively self-contained molecules and
which are frequently found in the blood serum.
These antibodies account for the classical reac-
tions of agglutination, complement fixation and
so forth. Further, several investigators have
shown that an appropriately timed course of
whole body irradiation or of one of several cancer
chemothcrapcutic drugs may sometimes be ar-
ranged so as to inhibit antibody formation to first
exposure to antigen (1, 2). For instance, a rabbit
given high doses of 6-mcrcaptopurine and then
injected with bovine serum albumin (BSA) fails
to make anti-BSA antibody, whereas BSA injec-
ted control rabbits produce anti-BSA antibody
of high titer (3).
In contrast to immediate hypersensitivity, a
convincing array of unrelated observations indi-
cates that the specific antibody-like stuff of
delayed hypersensitivity is intimately associated
with the circulating lymphocyte and is not found
freely circulating in the blood serum (4). In-
cluded in delayed allergy arc tuberculin hyper-
sensitivity, the homograft reaction, contact
dermatitis and, at least in part, organ allergies
such as allergic encephalitis. Pretreatment with
high doses of whole-body x-ray will inhibit the
acquisition of delayed hypersensitivity (5, 6).
However, the literature raises considerable qucs-
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tion as to whether a similar suppression of de-
layed hypersensitivity can be achieved with the
cancer chcmothcrapeutic drugs (7—11). This
study is directed at just that issue, namely—can
a delayed type sensitization following first expo-
sure to antigen be importantly frustrated by a
cancer chcmotherapcutic drug?
METHOD
Cyclophosphoramide (Cytoxan®) was the test
cancer chemotherapeutic drug. This compound
has found wide clinical use especially in lympho-
matous malignancy; in large dosages it will
produce leukopenia in man and guinea-pig.
Our model for delayed hypersensitivity is
DNCB (1-Chloro-2,4-dinitrobenzene) contact der-
matitis in the guinea-pig. Our sensitizing and
eliciting (challenging) procedures are an adapta-
tion of classical procedures.t Stock albino guinea
pigs are purchased from a local dealer; in a given
experiment control and experimental animals are
drawn from the same lot. Animals are sensitized
by a single intradermal injection into the shaved
pre-sacral skin of 0.1 cc. of a warmed solution of
1% DNCB in propylene glycol. A few days prior
to challenge a large area of the back is prepared by
zip® wax epilation. The challenge is made with
0.05 cc. of 0.1% DNCB in absolute ethyl alcohol
which material is pipetted onto a pre-marked
circular area 2.1 cm. in diameter. A warm air
current from a commercial hair dryer facilitates
evaporation of solvent; care is taken to uniformly
distribute the DNCB alcohol solution (Fig. 1
and 2). Reactions are read at 24 and 48 hours and
recorded according to classical criteria. Numer-
ous control studies have shown this DNCB chal-
lenge dose to be non-irritating to the non-sen-
sitized guinea-pig.
The experimental animals received daily IP
injections of cyclophosphoramide (10 mgm/d. X
14 d). On day 8 the experimental group as well as
a control group were injected with a sensitizing
dose of DNCB as described above. Both groups
were challenged at various later times; to avoid
the possibility of sensitizing the animals with our
challenge dose, we selected non-recurring aliquots
t As standardized by Bertil Magnusson, M.D.
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F's. 1. A non-irritated area on the ZIP®-epilated hack of the guinea pig is marked prior to challenge.
FIG. 2. The challenge dose is pipetted onto the test site.
of animals from each group for successive eliciting
tests as often as possible.
In a correlative experiment we set about to
determine the differential effect on delayed hyper-
sensitivity of a variety of anti-cancer drugs. We
used Actinomycin 1), vincaleukoblastine, 6-
mercaptopurine and cyclophosphoramide. These
compounds will be recognized for the heteroge-
ncity of their chemistry, pharmacology, toxicol-
ogy and therapeutic spectrum; of the four, only
cyclophosphorainidc induced marked leukopcnia
in the guinea-pigs. However, all these drugs arc
potent cellular poisons and were administered in
dosages close to or exceeding their LD,1s (Fig. 3).
Surviving animals were all sick during drug ad-
ministration and for a short time afterwards. All
4'
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4 experimental drug groups as well as an untreated
control group were injected with a sensitizing
dose of DNCB on the third day after start of drug
treatment.
RESULTS
Cyclophosphoramide clearly delays the onset
of DNCB contact dermatitis. (Fig. 4). This could
mean either (a) inhibition of sensitization or (b)
inhibition of challenge reaction (masking of sensi-
tization). To decide between these alternatives
we undertook the following control experiment.
Twenty guinea-pigs were sensitized to DNCB;
then they were treated with cyclophosphoramide
(10 mgm./d >< 14 d). After start of cyclophos-
phoramide these already sensitized animals were
challenged with DNCB every 2—3 days. Their
challenge responses appeared entirely like that of
a non-cyclophosphoramidized DNCB-sensitizcd
control group. Cyclophosphoramide did not sig-
nificantly alter the picture of the DNCB eliciting
reaction.
Projecting back to the main experiment, it is
clear that the cyclophusphoramide induced delay
in onset of DNCB contact dermatitis is due to
inhibition of the sensitization. WTe are not deal-
ing with sensitized animals who experimental
Three
Intraperitoneal Dosage ,
vors*
Cyclophosphora-
mide 10 mgm/d X 10 d. 16/20
6-Mercaptopurine.... 50 mgm/d X 10 d. 15/20
Vincaleukoblastine... 10 gamma/d)( 10 d. 12/20
Actinomycin D- 10 gamma/d X 10 d. 4/20
* Average weight of guinea-pigs at start of
experiment was 400 grams.
Fiu. 3
circumstance has made temporarily refractory to
challenge.
rrhe attempts to delay onset of hypersensitivity
with Actinomycin D, vinealeukoblastine and
6-mercaptopurine were entirely unsuccessful in
the correlative experiment; these animals became
sensitive at the same time and to the same degree
as the control animals. The failure with these
drugs is particularly noteworthy since the
guinea-pigs of all three groups, and especially of
the Actinomycin group, showed a marked mor-
bidity throughout the entire incubation period of
sensitivity (Fig. 3). Our positive controls, the
cyclophosphoramide animals, became sensitive
some fourteen days after the other guinea-pigs.
How does cyclophosphoramide inhibit the on-
set of delayed hypersensitivity? Cyclophosphor-
amide is a potent and unique cellular poison with
particularly high activity against nuclear protein.
The leukocyte is especially susceptible to its toxic
properties. Stated in a general way it seems
likely that the drug sabotages the antibody-
making machinery just at that time when it has
received rush production orders for large numbers
of a new commodity. The exact and necessary
site(s) of damage is not known; but that it is
temporary under the conditions of our experi-
ments is attested to by the later appearance of
fully-formed high-quality DNCB sensitivity.
SUMMARY
Cyclophosphoramide (Cytuxan®) pretreat-
ment greatly delays contact dermatitis type
sensitization to DNCB in the guinea-pig. Actino-
mycin D, vincaleukublastine and 6-mercapto-
purine in toxicologically comparable amounts
were completely unable to prolong the incubation
of the sensitivity.
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DISCUSSION
DR. RUDOLF L. BAEE (New York, N. Y.): I
enjoyed Dr. Maguire's paper very much. In
addition to the non-specific methods mentioned
by him, namely x-rays and anticancer drugs,
there are also specific measures for interfering
with the primary sensitization of the delayed
type to "simple" chemical compounds.
Three methods are known which apparently
achieve this. The first one was described by
Sulzberger and is based on the intravenous ad-
ministration of the specific allergenic agent prior
to cutaneous exposure. The second one was de-
scribed by Dr. Chase and was mentioned by
Dr. Dubos today, namely feeding of the specific
sensitizing agent prior to cutaneous exposure.
The third method is the one used by Rosenthal,
Harber and me, namely exposure during fetal
life either via feeding of pregnant guinea pigs or
via intraperitoneal administration in pregnant
guinea pigs.
The anticancer drug which Dr. Maguire used,
apparently produces a very short-lived suppres-
sion of the sensitization. With these specific other
methods, it appears possible that the interference
with the sensitization lasts much longer. How-
ever, I know of no studies which tell us exactly
how long this interference ["specifically acquired
tolerance"] does last.
Dn. WALTER F. LEVEE (Boston, Massachu-
setts): I would like to ask Dr. Maguire how long
the reaction lasted that appeared on the sixth
day in the Don-treated animals, and also how long
the reaction lasted in those animals who had been
given the cytoxan and in whom the reaction first
appeared on the twentieth day.
DR. CYRIL H. MARCH (New York, New York):
I would like to ask whether white cell counts
were performed in the animals which had re-
ceived the cytotoxic agents and whether lymph
node cytology was examined, whether there was
any difference between the counts after cytoxan
or after the other cytotoxic agents.
Du. CHARLEs 0. MENDEL5ON (Detroit, Michi-
gan): Along the same lines as Dr. March, I believe
that Dobson and probably Obaley and others in
treating patients with mycosis fungoides with
cytoxan have found a marked rise in eosinophils
almost routinely above 40 per cent in their cases.
In this light, would Dr. Maguire have any
idea as to what response there might be as far as
the adrenal and steroid changes which might be
effective in the aberrance of the controlled and
treated animals.
DR. HENRY C. MAGUIRE, JR. (in closing): I
wish to thank the discussors for their comments.
To answer the questions—Dr. Lever, we did
not follow the controls and the Cytoxan® treated
animals' hypcrsensitivities in terms of months.
Certainly, for the next several weeks, these ani-
mals remain unequivocally positive.
Dr. March, we did white blood counts and
this is discussed in the written presentation of
this paper.
Briefly, Actinomycin D, VLB and 6MP, the
first three drugs, very weakly depress the circu-
lating white count in the guinea pig. Cytoxan has
a more profound effect on the circulating white
count. It is our feeling that this leukopenia is a
crucial matter in the inhibition of the primary
sensitization reaction.
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We did not do lymph node histology.
Dr. Mendelson brings up the possibility (if I
am interpreting his question correctly) that we
may have been stimulating the adrenals and,
actually, getting a secondary blockade from
adrenal discharge.
We did not do measurements of steroid levels.
However, in terms of LD-50's, we gave the
actinomycin-D, VLB and 6-MP, the three drugs
that did not work, in more toxic quantities than
the Cytoxan®. And therefore, if we might be per-
mitted to speculate, we probably had more
steroid, a greater adrenal discharge, with these
three compounds than with the Cytoxan®.
